Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $284.00 at Morgan Stanley

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective hoisted by Morgan Stanley from $275.00 to $284.00 in a report released on Friday morning,Benzinga reports. The firm currently has an equal weight rating on the biopharmaceutical company’s stock.

ALNY has been the subject of a number of other reports. Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. Barclays upped their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Piper Sandler reaffirmed an “overweight” rating and set a $296.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Scotiabank upped their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research report on Friday, November 1st. Finally, TD Cowen upped their price target on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $299.43.

Alnylam Pharmaceuticals Trading Down 3.2 %

ALNY stock opened at $256.45 on Friday. The company has a market cap of $33.08 billion, a price-to-earnings ratio of -97.88 and a beta of 0.35. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The business has a fifty day simple moving average of $254.03 and a 200-day simple moving average of $263.14. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, equities research analysts expect that Alnylam Pharmaceuticals will post -2.24 EPS for the current year.

Insider Buying and Selling

In related news, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of the firm’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at $3,416,865. This represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 73,964 shares of company stock worth $20,622,925. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Mercer Global Advisors Inc. ADV bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth about $612,000. Comerica Bank lifted its holdings in Alnylam Pharmaceuticals by 631.7% in the fourth quarter. Comerica Bank now owns 13,991 shares of the biopharmaceutical company’s stock worth $3,292,000 after acquiring an additional 12,079 shares during the last quarter. Voleon Capital Management LP bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth about $8,749,000. Utah Retirement Systems lifted its holdings in Alnylam Pharmaceuticals by 1.9% in the fourth quarter. Utah Retirement Systems now owns 21,325 shares of the biopharmaceutical company’s stock worth $5,018,000 after acquiring an additional 400 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC lifted its holdings in Alnylam Pharmaceuticals by 355.7% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 127,000 shares of the biopharmaceutical company’s stock worth $29,884,000 after acquiring an additional 99,133 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.